Brown A E, Nelson K E, Makonkawkeyoon S, Vithayasai V, Scollard D M, Bullock W E
Int J Lepr Other Mycobact Dis. 1985 Dec;53(4):559-64.
To test the capacity of cimetidine to enhance cellular immunity in patients with lepromatous leprosy (LL), cimetidine was given for one month to 29 inactive LL patients and 3 active LL patients. Immune function was monitored with skin tests (lepromin, PPD, candida, and trichopytin), lymphocyte transformation tests (phytohemagglutinin, BCG, and Dharmendra lepromin), and quantitation of peripheral blood lymphocyte subpopulations. A small but significant "booster" response to PPD was the only change observed in the study of patients with inactive disease, and leprosy-related reactions did not occur. In the few active LL patients studied, neither immune enhancement nor leprosy-related reactions were observed. The results of this investigation suggest that cimetidine can be used safely in patients with inactive lepromatous leprosy.
为测试西咪替丁增强瘤型麻风(LL)患者细胞免疫的能力,对29例静止期LL患者和3例活动期LL患者给予西咪替丁治疗1个月。通过皮肤试验(麻风菌素、结核菌素纯蛋白衍生物、念珠菌和发癣菌素)、淋巴细胞转化试验(植物血凝素、卡介苗和达曼德拉麻风菌素)以及外周血淋巴细胞亚群定量来监测免疫功能。在对静止期疾病患者的研究中,观察到的唯一变化是对结核菌素纯蛋白衍生物有轻微但显著的“增强”反应,且未发生麻风相关反应。在少数研究的活动期LL患者中,既未观察到免疫增强,也未观察到麻风相关反应。本研究结果表明,西咪替丁可安全用于静止期瘤型麻风患者。